PDS Biotech’s PDS01ADC Delivers Impressive 78% Response Rate in Advanced Colorectal Cancer Trial
PDS Biotech drug PDS01ADC improved tumor shrinkage and survival in colorectal cancer trials, showing strong early results.
/ 111 items
#XY Event-Driven Stocks↓
Immutep Scores FDA Orphan Drug Win for Rare Cancer Treatment Efti
Immutep’s efti shows strong tumor shrinkage in rare cancer STS, earning FDA orphan status to speed development and approval.
Praxis Precision Medicines Shares Surge After FDA Accepts NDA for Ulixacaltamide in Essential Tremor
Praxis Precision Medicines stock jumps as Food and Drug Administration reviews new tremor drug showing strong results and safety.
Obsidian Therapeutics to Merge with Galera and Raise $350 Million to Advance TIL Cell Therapy
Galera and Obsidian merge to form OBX, advancing TIL cancer therapy for melanoma & lung cancer, backed by $350M funding.
Avanos Medical to Be Acquired by American Industrial Partners for $1.27 Billion
Avanos Medical is being bought by AIP for $1.27B in cash. Shareholders get $25 per share, a big premium. Company goes private in 2026.
Travere Wins Full FDA Approval for FILSPARI – First-Ever Treatment for Rare Kidney Disease FSGS
FDA approved FILSPARI for FSGS kidney disease, showing it lowers protein in urine and slows damage. It offers a new treatment option for patients with few choices.